Denali Therapeutics Inc
DNLI13.894USD
+0.454+3.38%
Horário de mercado （ET）Cotações atrasadas em 15 min
2.02BValor de mercado
PerdaP/L TTM
Mais detalhes de Denali Therapeutics Inc Empresa
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
Informações da empresa
Código da empresaDNLI
Nome da EmpresaDenali Therapeutics Inc
Data de listagemDec 08, 2017
CEODr. Ryan J. Watts, Ph.D.
Número de funcionários422
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 08
Endereço161 Oyster Point Blvd.
CidadeSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94080
Telefone16508668547
Sitehttps://www.denalitherapeutics.com
Código da empresaDNLI
Data de listagemDec 08, 2017
CEODr. Ryan J. Watts, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Ryan J. Watts, Ph.D.
Dr. Ryan J. Watts, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.46M
--
Dr. Alexander O. Schuth, M.D.
Dr. Alexander O. Schuth, M.D.
Chief Operating and Financial Officer, Secretary
Chief Operating and Financial Officer, Secretary
768.06K
+20.52%
Dr. Carole Ho, M.D.
Dr. Carole Ho, M.D.
Chief Medical Officer, Head of Development
Chief Medical Officer, Head of Development
383.89K
+50.87%
Mr. Jay T. Flatley
Mr. Jay T. Flatley
Independent Director
Independent Director
352.53K
+1.74%
Dr. David P. Schenkein, M.D.
Dr. David P. Schenkein, M.D.
Independent Director
Independent Director
72.72K
+9.05%
Mr. Peter S. Klein
Mr. Peter S. Klein
Independent Director
Independent Director
27.53K
+28.08%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
26.07K
+30.13%
Dr. Marc Tessier-Lavignec, Ph.D.
Dr. Marc Tessier-Lavignec, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven E. (Steve) Krognes
Mr. Steven E. (Steve) Krognes
Director
Director
--
--
Ms. Nancy A. Thornberry
Ms. Nancy A. Thornberry
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Ryan J. Watts, Ph.D.
Dr. Ryan J. Watts, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.46M
--
Dr. Alexander O. Schuth, M.D.
Dr. Alexander O. Schuth, M.D.
Chief Operating and Financial Officer, Secretary
Chief Operating and Financial Officer, Secretary
768.06K
+20.52%
Dr. Carole Ho, M.D.
Dr. Carole Ho, M.D.
Chief Medical Officer, Head of Development
Chief Medical Officer, Head of Development
383.89K
+50.87%
Mr. Jay T. Flatley
Mr. Jay T. Flatley
Independent Director
Independent Director
352.53K
+1.74%
Dr. David P. Schenkein, M.D.
Dr. David P. Schenkein, M.D.
Independent Director
Independent Director
72.72K
+9.05%
Mr. Peter S. Klein
Mr. Peter S. Klein
Independent Director
Independent Director
27.53K
+28.08%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 25 de jul
Atualizado em: sex, 25 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Baillie Gifford & Co.
8.32%
The Vanguard Group, Inc.
8.10%
Wellington Management Company, LLP
7.85%
BlackRock Institutional Trust Company, N.A.
6.91%
Fidelity Management & Research Company LLC
5.02%
Other
63.80%
Investidores
Investidores
Proporção
Baillie Gifford & Co.
8.32%
The Vanguard Group, Inc.
8.10%
Wellington Management Company, LLP
7.85%
BlackRock Institutional Trust Company, N.A.
6.91%
Fidelity Management & Research Company LLC
5.02%
Other
63.80%
Tipos de investidores
Investidores
Proporção
Investment Advisor
50.41%
Investment Advisor/Hedge Fund
27.07%
Hedge Fund
10.45%
Individual Investor
4.94%
Corporation
4.93%
Sovereign Wealth Fund
4.42%
Research Firm
2.34%
Pension Fund
0.51%
Bank and Trust
0.30%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
524
153.35M
105.55%
-12.15M
2025Q1
537
151.12M
104.03%
-14.77M
2024Q4
523
145.56M
100.28%
-21.13M
2024Q3
518
152.07M
106.51%
-14.19M
2024Q2
504
147.18M
103.45%
-5.80M
2024Q1
491
145.33M
102.36%
+2.75M
2023Q4
499
138.06M
99.94%
+3.21M
2023Q3
492
132.50M
96.48%
-2.55M
2023Q2
504
131.32M
95.95%
-3.31M
2023Q1
503
131.21M
95.98%
-630.06K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Baillie Gifford & Co.
12.09M
8.32%
-223.89K
-1.82%
Mar 31, 2025
The Vanguard Group, Inc.
11.77M
8.1%
-221.47K
-1.85%
Mar 31, 2025
Wellington Management Company, LLP
11.41M
7.85%
+1.56M
+15.86%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
10.04M
6.91%
-56.41K
-0.56%
Mar 31, 2025
Fidelity Management & Research Company LLC
7.29M
5.02%
-712.15K
-8.90%
Mar 31, 2025
Biogen Inc
7.16M
4.93%
-5.60M
-43.89%
Oct 30, 2024
Temasek Holdings Pte. Ltd.
5.36M
3.69%
--
--
Mar 31, 2025
UBS Asset Management (Switzerland)
4.88M
3.36%
+1.49M
+43.92%
Mar 31, 2025
Capital Research Global Investors
4.77M
3.28%
-712.07K
-13.00%
Mar 31, 2025
State Street Global Advisors (US)
4.46M
3.07%
-84.22K
-1.85%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Neuroscience and Healthcare ETF
4.17%
Tema Neuroscience and Mental Health ETF
2.07%
ALPS Medical Breakthroughs ETF
1.37%
Global X Guru Index ETF
1.24%
Virtus LifeSci Biotech Clinical Trials ETF
0.84%
BNY Mellon Innovators ETF
0.47%
SPDR S&P Biotech ETF
0.43%
Global X Aging Population ETF
0.33%
iShares Health Innovation Active ETF
0.26%
Direxion Daily S&P Biotech Bull 3X Shares
0.25%
Ver Mais
iShares Neuroscience and Healthcare ETF
Proporção4.17%
Tema Neuroscience and Mental Health ETF
Proporção2.07%
ALPS Medical Breakthroughs ETF
Proporção1.37%
Global X Guru Index ETF
Proporção1.24%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.84%
BNY Mellon Innovators ETF
Proporção0.47%
SPDR S&P Biotech ETF
Proporção0.43%
Global X Aging Population ETF
Proporção0.33%
iShares Health Innovation Active ETF
Proporção0.26%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.25%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
